? Oregon is one of a few states where methamphetamine (MA) abusers without a greater history of cocaine abuse are recruited for clinical research. The Methamphetamine Abuse Research Center (MARC) will characterize effects of MA administration and withdrawal at molecular, neurochemical, anatomical, behavioral, and clinical levels, to identify obstacles to recovery in MA abusers. Overarching themes addressed in preclinical and clinical research components using common methodologies include neuroadaptation to MA, neuroanatomy of MA-related behaviors, stressor responsivity, and impulsivity. Human and animal protocols inform one another with respect to these themes, forming the basis for bidirectional translational research. The Center's Administrative Core facilitates interactions among MARC investigators, and the Biostatistics Core analyzes associations and correlations within and across components. The Animal Core breeds and maintains genetically selected lines and other strains, and provides them to MARC investigators. The Education Core coordinates the research training of M.D. and Ph.D. pre- and postdoctoral fellows, and organizes and disseminates both clinical and preclinical information from MARC investigators to Centers and Oregon's rural areas that are impacted by MA production and abuse. Scientific Component 5 correlates acetylcholine release with active and passive administration of MA and provides neuroanatomic and molecular signaling data relevant to MA seeking for use in other components. Scientific Component 6, examines genetic influences, and behavioral and neurochemical correlates (in collaboration with Component 5) in mice selected for differences in MA-induced neuroadaptation and MA self-administration. Nomination of genetic candidates from this preclinical work could inform treatment strategies in clinical Component 7, and specific genetic associations can be pursued in patients from clinical components. Scientific Component 7 evaluates the relationship between symptom severity at intake and treatment failure in inpatients, tests (3-receptor and cholinergic medications, and conducts human laboratory evaluations of stressor responsivity. Component 8, the Pilot Projects, provides a means to support the development of multiple new directions in research on MA abuse. Thus, the MARC's themes address clinically relevant issues using innovative multidisciplinary approaches. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
1P50DA018165-01A1
Application #
7014240
Study Section
Special Emphasis Panel (ZDA1-RXL-E (03))
Program Officer
Frankenheim, Jerry
Project Start
2006-09-01
Project End
2011-06-30
Budget Start
2006-09-01
Budget End
2007-06-30
Support Year
1
Fiscal Year
2006
Total Cost
$993,212
Indirect Cost
Name
Oregon Health and Science University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Shabani, Shkelzen; Schmidt, Bryan; Ghimire, Bikalpa et al. (2018) Depression-like symptoms of withdrawal in a genetic mouse model of binge methamphetamine intake. Genes Brain Behav :e12533
Eshleman, Amy J; Nagarajan, Shanthi; Wolfrum, Katherine M et al. (2018) Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology (Berl) :
McCready, Holly; Kohno, Milky; Kolessar, Michael et al. (2018) Functional MRI and delay discounting in patients infected with hepatitis C. J Neurovirol 24:738-751
Loftis, Jennifer M; Valerio, Juno; Taylor, Jonathan et al. (2018) S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder. Alcohol Clin Exp Res :
Eshleman, Amy J; Wolfrum, Katherine M; Reed, John F et al. (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27-34
Tosh, Dilip K; Ciancetta, Antonella; Mannes, Philip et al. (2018) Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. ACS Omega 3:12658-12678
McCarty, Dennis; Priest, Kelsey C; Korthuis, P Todd (2018) Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. Annu Rev Public Health 39:525-541
Eastwood, Emily C; Eshleman, Amy J; Janowsky, Aaron et al. (2018) Verification of a genetic locus for methamphetamine intake and the impact of morphine. Mamm Genome 29:260-272
Kohno, Milky; Dennis, Laura E; McCready, Holly et al. (2018) A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug Alcohol Depend 192:186-192
Holton, Dwight; White, Elizabeth; McCarty, Dennis (2018) Public Health Policy Strategies to Address the Opioid Epidemic. Clin Pharmacol Ther 103:959-962

Showing the most recent 10 out of 143 publications